Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
AARTIDRUGS.NS
Strong BuyPremium GrowerAarti Drugs Limited · Healthcare · India · $406M · Avg Vol: $910K/d
80
StockRankGet insider-trade alerts
Q
64
V
49
M
63
P/E (TTM)
20.2x
ROE
12.6%
D/E
0.4x
Dividend %
0.5%
COMPANY DESCRIPTION
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27.1B | 25.1B | 23.7B | 25.2B | -2.3% | 26.8B | 28.9B | 32.1B | 12.9% |
| EPS (INR) | 17.97 | 18.56 | 18.35 | 21.36 | 5.9% | 20.95 | 23.70 | 27.90 | 14.3% |
| Shares | 92.6M | 91.9M | 91.3M | 91.3M | -1.4% | 91.3M | — | — | — |
| Debt | 6.1B | 5.6B | 6.2B | 5.8B | -1.8% | 5.8B | — | — | — |
| Equity | 11.9B | 12.8B | 13.7B | 15.5B | 9.1% | — | — | — | — |
| Op CF | 1.3B | 3.6B | 2.4B | 2.5B | 23.9% | 2.5B | — | — | — |
| Inv CF | -1.6B | -2.2B | -1.6B | -1.7B | — | — | — | — | — |
| Fin CF | 165.4M | -1.4B | -821.2M | -774.4M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+3.0%
SMA 50SMA 200
Close
$4.45
RSI (14)
59.8
52W High
$5.59
From 52W High
0.8%
SCORE BREAKDOWN
Quality
64
ROIC
13.9%80.8
ROE
12.6%77.2
GP/Assets
35.7%71.9
Op. Margin
11.5%66.6
FCF/Assets
2.8%59.5
Piotroski
668.8
Int. Cover
7.7x57.5
D/E Ratio
0.37x35.9
Current Ratio
1.59x28.8
Value
49
P/E (TTM)
20.2x59.3
EV/EBITDA
13.1x56.2
P/FCF
48.1x30.5
P/B
2.5x53.6
P/S
1.4x76.5
Div Yield
0.5%14.3
Momentum
63
52W High %
80%66.0
RS 6M
24%82.7
SMA 50/200
1.07x70.7
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+33%44.2
Q Growth
-7%31.6
FUNDAMENTALS
Market Cap
$406M
P/E (Forward)
15.2x
Gross Margin
37.5%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AARTIDRUGS.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AARTIDRUGS.NS | Aarti Drugs Limited(you) | $406M | 80 | Strong Buy |
| SOLARA.NS | Solara Active Pharma Sciences Limited | $357M | 81 | Strong Buy |
| INDSWFTLAB.NS | Ind-Swift Laboratories Limited | $356M | 81 | Strong Buy |
| RPGLIFE.NS | RPG Life Sciences Limited | $489M | 79 | Buy |
| UNICHEMLAB.NS | Unichem Laboratories Limited | $413M | 87 | Strong Buy |
| SAKAR.NS | Sakar Healthcare Limited | $268M | 79 | Buy |
| HIKAL.NS | Hikal Limited | $320M | 75 | Buy |
| FDC.NS | FDC Limited | $594M | 76 | Buy |
| GUFICBIO.NS | Gufic Biosciences Limited | $466M | 71 | Buy |
| INNOVACAP.NS | Innova Captab Limited | $707M | 79 | Buy |
Peer medians: ROE 11.8% · P/E 42.8x · Gross margin 59.4%